Lactobacillus Or Pediococcus Or Leuconostoc Patents (Class 424/93.45)
  • Patent number: 10286026
    Abstract: The invention covers a novel treatment strategy that considerably improves conventional probiotic treatments of inflammatory bowel diseases, irritable bowel syndrome and other gastrointestinal disorders. Both probiotic microorganisms and the carrier of the probiotic microorganisms in form of a fermented cereal gruel are used as treatment effectors. Phospholipids may also be an effecter. The novel treatment strategy is capable of removing the symptoms of inflammatory bowel diseases regardless of a mild, moderate or severe stage of the disease.
    Type: Grant
    Filed: February 15, 2017
    Date of Patent: May 14, 2019
    Assignee: NORDIC REBALANCE A/S
    Inventor: Hans Israelsen
  • Patent number: 10272100
    Abstract: Disclosed is a non-reducing end unsaturated mannuronic acid oligosaccharide having a molecular weight of 100-3000 Da, which is obtained by lysing polymannuronate as a substrate with alginate lyase, and provided are: a non-reducing end unsaturated mannuronic acid oligosaccharide; and pharmaceutical compositions for alleviating, preventing, or treating obesity, diabetes, and climacteric syndrome, and probiotics for promoting intestinal beneficial bacteria, the compositions and probiotics containing, as an active ingredient, the non-reducing end unsaturated mannuronic acid oligosaccharide, so that the antiobesity and antidiabetic effects, estrogen activity, and intestinal microflora controlling effect of the non-reducing end unsaturated mannuronic acid oligosaccharides are remarkably excellent as compared with non-reducing end saturated mannuronic acid oligosaccharides.
    Type: Grant
    Filed: August 15, 2017
    Date of Patent: April 30, 2019
    Assignee: INDUSTRY FOUNDATION OF CHONNAM NATIONAL UNIVERSITY
    Inventor: Du Woon Kim
  • Patent number: 10265350
    Abstract: The invention relates to products and compositions that may be beneficial in animal husbandry. Said products and compositions comprise microorganisms, such as bacteria, and probiotic bacteria in particular. Thus, provided herein are microbial strains, as well as selection criteria which will enable the skilled reader to find further strains useful in the present invention. The strains, as well as compositions comprising the same, may be administered to animals, farmed animals such as swine in particular. The administration may occur in the first days of life. By administration of the products or compositions of the inventions animal growth can be promoted and animal weight can be increased. Bacterial infections may also be prevented or treated by said compounds or compositions.
    Type: Grant
    Filed: September 25, 2013
    Date of Patent: April 23, 2019
    Assignees: UNIVERSIDAD DE LEON, AQUILON CYL SOCIEDAD LIMITADA
    Inventors: Pedro Miguel Rubio Nistal, Ana María Carvajal Urueña, Marta García Díez
  • Patent number: 10265351
    Abstract: Provided is a bacterial composition which comprises from 104 to 1012 cfu/g of Pediococcus pentosaceus cells which have the ability to induce the production of interleukin-10 to reduce inflammation in the intestinal tract among other features and is useful in the amelioration of excessive crying in infants.
    Type: Grant
    Filed: August 7, 2014
    Date of Patent: April 23, 2019
    Assignees: AB-BIOTICS, S.A., VANPHARMA LABORATORIOS, S. A.
    Inventors: Jordi Cune Castellana, Elisabet Lazaro Mallen, Jordi Espadaler Mazo
  • Patent number: 10251914
    Abstract: The present invention provides compositions that include an extract of human feces, and methods for using such compositions, including methods for replacing or supplementing or modifying a subject's colon microbiota, and methods for treating a disease, pathological condition, and/or iatrogenic condition of the colon.
    Type: Grant
    Filed: June 19, 2017
    Date of Patent: April 9, 2019
    Assignee: Regents of the University of Minnesota
    Inventors: Michael J. Sadowsky, Alexander Khoruts, Alexa R. Weingarden, Matthew J. Hamilton
  • Patent number: 10245289
    Abstract: An embodiment is a method of preventing, mitigating or treating Lupus that includes administering an effective amount of a medicament to a human comprised of Lactobacillus bulgaricus B-30892 and/or a supernatant resulting from culturing Lactobacillus bulgaricus B-30892 and/or bioactive materials resulting from culturing Lactobacillus bulgaricus B-30892 to prevent, mitigate or treat Lupus.
    Type: Grant
    Filed: December 14, 2016
    Date of Patent: April 2, 2019
    Assignee: NuBiome, Inc.
    Inventor: Brian C. Lue
  • Patent number: 10245290
    Abstract: The present invention relates to at least one probiotic strain chosen from Lactobacillus paracasei, or at least one probiotic strain chosen from Lactobacillus paracaseiin combination with at least one probiotic strain chosen from Lactobacillus plantarum, for use in the treatment or prevention of osteoporosis or for use in increasing the absorption of at Ca2+ ions, in a mammal, preferably in a human.
    Type: Grant
    Filed: April 3, 2014
    Date of Patent: April 2, 2019
    Assignee: Probi AB
    Inventors: Anna Berggren, Niklas Larsson, Gunilla Önning, Irini Lazou Ahrén, Klara Sjögren, Claes Ohlsson
  • Patent number: 10238696
    Abstract: Lactic acid bacteria, which are isolated Lactococcus lactis subsp. lactis LL358 and isolated Lactobacillus salivarius LS159 respectively. By administering a composition comprising the lactic acid bacteria of the invention, renal injury, metabolic syndrome, hyperuricemia, hypocalcemia, and other disorders can be effectively ameliorated or treated.
    Type: Grant
    Filed: December 5, 2016
    Date of Patent: March 26, 2019
    Assignee: NEW BELLUS ENTERPRISES CO., LTD.
    Inventors: Chun-Chih Huang, Wen-Ying Huang, Hsueh Fang Wang, Paik Seong Lim, Pin Hsiu Liu
  • Patent number: 10238674
    Abstract: Oligosaccharides from bovine milk, whey and dairy products, and methods of producing bovine milk oligosaccharides are provided.
    Type: Grant
    Filed: July 20, 2017
    Date of Patent: March 26, 2019
    Assignee: The Regents of the University of California
    Inventors: J. Bruce German, David Mills, Carlito B. Lebrilla, Daniela Barile, Riccardo LoCascio
  • Patent number: 10232001
    Abstract: The present invention comprises a method for selecting lactic acid bacterial strains effective for preventing bone loss in humans and strains that have been selected according to the presented method. The selection method is based on the strain's capability of reestablishing an altered microbial community to normal and/or harboring at least one of four specific SNPs.
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: March 19, 2019
    Assignees: BioGaia AB, Board of Trustees of Michigan State University
    Inventors: Eamonn Connolly, Robert Allen Britton, Laura Rae McCabe
  • Patent number: 10183046
    Abstract: A first aspect of the invention relates to a porcine lactic acid bacterial strain, wherein said bacterial strain is characterised by one or more of the following characteristics: (i) the ability to exhibit antimicrobial activity against E. coli; (ii) the ability to exhibit antimicrobial activity against S. enteritidis; (iii) the ability to suppress inflammation in IPEC cells induced by 12-0-tetradecaboylphorbol-13-acetate (PMA); (iv) the ability to block the attachment or invasion of IPEC cells by S. enteritidis; (v) the ability to block the attachment or invasion of IPEC cells by E. coli; (vi) the absence of antibiotic resistance to one or more antibiotics selected from the following: ampicillin; cefotaxime; chloramphenicol; erythromycin; gentamicin; tetracycline; vancomycin; metronizadole; nalidixic acid; and kanamycin; and (vii) the ability to exhibit heat stability when subjected to three cycles of heating, each cycle comprising heating at a temperature of 70° C. for a period of 15 minutes.
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: January 22, 2019
    Assignee: 4D Pharma Research Limited
    Inventor: Denise Kelly
  • Patent number: 10174388
    Abstract: A method is provided for evaluating agents for the treatment of different intestinal motility disorders, using distinct methodological parts related to musculature and nerves of the GI tract which communicate with the brain. In particular, the present invention provides a method for the selection of an agent effective for the treatment of an intestinal motility disorder, wherein the method comprises: a) a step of spatiotemporal (ST) mapping carried out on a gastrointestinal segment to analyze the effect of the agent on gastrointestinal motility; and b) a step of ex vivo nerve bundle recording carried out on a gastrointestinal segment to analyze the effect of the agent on mesenteric afferent nerve firing. Bacterial strains selected by the methods of the invention and the use of the bacterial strains in the treatment of intestinal motility disorders are also provided.
    Type: Grant
    Filed: September 15, 2017
    Date of Patent: January 8, 2019
    Assignee: BioGaia AB
    Inventors: Eamonn Connolly, Wolfgang Kunze, John Bienenstock
  • Patent number: 10172793
    Abstract: A probiotic tablet comprising a probiotic micro-organism and other nutritionally active ingredients in two zones, a first zone comprising said probiotic micro-organism and prcicrably selenium, and a second zone comprising at least one said other active ingredient such as iron, other minerals and vitamin B6 kept separated from the probiotic micro-organism of said first zone, the water activity in said probiotic micro-organism containing first zone being no greater than 0.2 and the water content of said tablet being as much as 3% by weight. Good viability of the micro-organisms is obtained despite the relatively high overall moisture content.
    Type: Grant
    Filed: December 21, 2004
    Date of Patent: January 8, 2019
    Assignee: Ferrosan A.S.
    Inventors: Kristian Lund Henriksen, Helene Mathilda Mortensen, Marianne Winning
  • Patent number: 10166262
    Abstract: The invention is directed to a novel strain of Lactobacillus plantarum AMT14 and compositions comprising the same.
    Type: Grant
    Filed: April 20, 2017
    Date of Patent: January 1, 2019
    Inventors: Ewelina Sosnowska-Turek, Jaroslaw Piotr Turek
  • Patent number: 10159700
    Abstract: A composition of Lactobacillus fermentum GMNL-296 and a use of Lactobacillus fermentum GMNL-296 for producing a composition to improve the infection symptoms of Clostridium difficile are provided. The Lactobacillus fermentum GMNL-296 is to promote the expression of anti-inflammatory cytokine IL-10 and Treg cell related transcription factors, so that the infection symptoms of weight loss and intestinal abnormalities are improved.
    Type: Grant
    Filed: December 1, 2016
    Date of Patent: December 25, 2018
    Assignee: GENMONT BIOTECH INC.
    Inventors: Yi-Hsing Chen, Wan-Hua Tsai
  • Patent number: 10149869
    Abstract: The disclosure provides oral compositions and methods of using such compositions in treating subjects infected with one or more hepatic disorders. The compositions include lysates or cell wall extracts of one or more gram positive bacteria, exhibit particular activity against hepatitis C virus (HCV), and may be useful in treating those infected with HCV as well as other hepatic diseases or disorders. Also described are methods of treating a hepatic disease or disorder by administering a therapeutically effective amount of at least one therapeutically active agent capable of upregulating or downregulating the Complement system pathway, wherein the therapeutically active agent enhances the formation of one or more convertase enzymes.
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: December 11, 2018
    Assignee: Labyrinth Holdings, LLC
    Inventor: Elizabeth McKenna
  • Patent number: 10149872
    Abstract: Provided is the new strain Lactobacillus pentosus CECT 7504 and compositions and products comprising said strain and uses in the prevention and/or treatment of candidiasis (oral, intestinal and vaginal) and of bacterial vaginosis.
    Type: Grant
    Filed: August 11, 2014
    Date of Patent: December 11, 2018
    Assignee: Gynea Laboratorios, S.L.
    Inventors: Jordi Espadaler Mazo, Miguel Angel Losada Diaz
  • Patent number: 10124016
    Abstract: Disclosed is a nutritional composition comprising a combination of non-digestible oligosaccharides and a product obtained by incubating an aqueous substrate by bifidobacteria and optionally a product obtained by incubating an aqueous substrate by S. thermophilus. Said combination synergistically improves the immune system by stimulating the Th1 response, and/or decreasing the Th2 response, improving the vaccination response, improving the resistance against infections and/or decreasing allergy.
    Type: Grant
    Filed: January 13, 2017
    Date of Patent: November 13, 2018
    Assignee: N.V. NUTRICIA
    Inventors: Belinda Potappel-Van 'T Land, Leon Matthieu Johannes Knippels, Alma Jildou Nauta, Johan Garssen
  • Patent number: 10117832
    Abstract: Provided herein are methods and processes for emulsifying non-polar compounds, such as omega fatty acids. Also provided are compositions that can be prepared according to the methods and processes described herein. The compositions, for example, have a high amount of the non-polar compound, such as a large amount of omega fatty acids. The non-polar compounds are also present in very small droplets within composition. For example, the mean or median particle size of the droplets is less than about 5 ?m. Further, the composition includes a low amount of surfactant, such as less than about 10-15% of the surfactant.
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: November 6, 2018
    Assignee: BARLEAN'S ORGANIC OILS, LLC
    Inventor: Peter Nguyen
  • Patent number: 10087241
    Abstract: This disclosure describes a fusion polypeptide that includes an anchor domain and a binding domain that specifically binds to a target biofilm. The anchor domain generally includes at least a portion of a cell membrane polypeptide. The binding domain includes a sufficient portion of a polypeptide that specifically binds to a component of a target biofilm to specifically bind to the target biofilm. This disclosure also describes cells that include the fusion polypeptide and methods involving the use of such cells.
    Type: Grant
    Filed: March 24, 2016
    Date of Patent: October 2, 2018
    Assignee: REGENTS OF THE UNIVERSITY OF MINNESOTA
    Inventors: Christine Elizabeth Salomon, Joshua D. Erickson
  • Patent number: 10066233
    Abstract: The present invention relates to the use of one or more cas genes for modulating resistance in a cell against a target nucleic acid or a transcription product thereof.
    Type: Grant
    Filed: August 25, 2006
    Date of Patent: September 4, 2018
    Assignee: DUPONT NUTRITION BIOSCIENCES APS
    Inventors: Rodolphe Barrangou, Patrick Boyaval, Christophe Fremaux, Philippe Horvath, Dennis Romero
  • Patent number: 10064902
    Abstract: The invention relates to a novel strain of Bifidobacterium animals ssp. animalis, which is able, inter alia, to improve the function of the enteric nervous system, and to compositions said novel strain.
    Type: Grant
    Filed: December 10, 2013
    Date of Patent: September 4, 2018
    Assignee: COMPAGNIE GERVAIS DANONE
    Inventors: Sophie Legrain-Raspaud, Gianfranco Grompone, Sandrine Capronnier, Tamara Smokvina, Marie-Christine Degivry, Biliana Lesic, Michel Neunlist
  • Patent number: 10052354
    Abstract: It is to provide a composition derived from lactic acid bacteria having an anti-allergic effect (an effect of suppressing allergic symptoms such as hay fever) synergistically, and a food product, pet food, etc. containing the composition. It is to prepare a composition having an anti-allergic action, containing Lactobacillus crispatus KT-11 strain, KT-23 strain, or KT-25 strain bacterial cells and viable bacteria, dead bacteria, or a processed product of bacterial cells of other lactic acid bacteria belonging to the genus Lactobacillus, genus Bifidobacterium, genus Leuconostoc, genus Enterococcus, genus Pediococcus, etc. at a biomass-converted ratio of 99:1 to 50:50, preferably 99:1 to 75:25.
    Type: Grant
    Filed: March 4, 2011
    Date of Patent: August 21, 2018
    Assignee: KITII CO., LTD.
    Inventors: Keisuke Tobita, Hajime Otani
  • Patent number: 10028981
    Abstract: The present invention generally relates to the field of probiotic bacteria. In particular it relates to methods for treating functional GI disorders comprising administering Bifidobacterium longum, such as Bifidobacterium longum ATCC BAA-999.
    Type: Grant
    Filed: August 24, 2010
    Date of Patent: July 24, 2018
    Assignee: Nestec S.A.
    Inventors: Peter McLean, Gabriela Bergonzelli de Gonda, Stephen Michael Collins, Premysl Bercik, Elena Verdu de Bercik
  • Patent number: 10028983
    Abstract: Inoculation of ATM-deficient mice with probiotic microorganisms, such as L. johnsonii, changed immune parameters, decreased a marker of DNA damage and increased the lifespan of the mice. Compositions and methods described herein are useful for the treatment and prevention of Ataxia telangiectasia and other cancer-prone diseases, such as p53 deficiency-associated cancers. Compositions and methods of the present invention are also useful for treating and preventing radiation-induced toxicity to normal tissue in a subject being exposed to radiation. Compositions and methods of the invention can increase lifespan in a simple, non-invasive manner.
    Type: Grant
    Filed: February 19, 2014
    Date of Patent: July 24, 2018
    Assignee: The Regents of the University of California
    Inventors: Mitsuko L. Yamamoto, Robert H. Schiestl, Ramune Reliene, James Borneman, Laura L. Presley, Jonathan Braun
  • Patent number: 10022407
    Abstract: Provided are the use of Lactobacillus rhamnosus strain CNCM I-3690 for reducing diet-induced weight gain and/or diet-induced insulin resistance, and treating disorders resulting therefrom, such as overweight, obesity and obesity-related disorders in a subject.
    Type: Grant
    Filed: November 12, 2012
    Date of Patent: July 17, 2018
    Assignees: Compagnie Gervais Danone, Tufts University
    Inventors: Jian Shen, Jingjing Wang, Liping Zhao, Martin Saul Obin, Muriel Derrien, Emilie Rocher, Johan Van Hylckama Vlieg
  • Patent number: 10004771
    Abstract: The subject invention provides materials and methods that effectively support innate immunity and/or disperse pathogenic biofilms using readily available, nontoxic, natural substances, while supporting restoration of normal microbiotic homeostasis. In one embodiment, the subject invention provides anti-biofilm compositions comprising one or more probiotic organisms, anti-microbial honey, and other ingredients such as prebiotic compounds, other hive products, green tea derivatives, other plant derivatives, and vitamin D3.
    Type: Grant
    Filed: April 11, 2017
    Date of Patent: June 26, 2018
    Assignee: QUORUM INNOVATIONS, LLC
    Inventors: Eva A. Berkes, Nicholas T. Monsul, Frederick T. Boehm
  • Patent number: 10004770
    Abstract: A method is provided of selecting specific probiotic lactic acid bacteria producing histamine and the use of such strains for beneficial effects for mammals. The method includes selecting a lactic acid bacterial strain for use in the local production of histamine in a mammal, and further comprises screening bacteria for the presence of an active histidine operon and selecting a strain which has an active histidine operon and is capable of producing histamine. Preferably said strain is selected for its ability to produce histamine at a level of greater than 250 pg/ml. The present invention further provides products comprising the strains obtainable by the selection methods of the invention for use in the local production of histamine in a mammal, in particular for use in the treatment or prophylaxis of inflammatory conditions.
    Type: Grant
    Filed: October 10, 2016
    Date of Patent: June 26, 2018
    Assignee: BIOGAIA AB
    Inventors: James Versalovic, Carissa Michelle Thomas, Eamonn Connolly
  • Patent number: 9980491
    Abstract: A probiotic composition and methods for the mitigation, inhibition, and/or exclusion of microorganisms.
    Type: Grant
    Filed: July 25, 2015
    Date of Patent: May 29, 2018
    Inventor: Siobhan Reilly
  • Patent number: 9962416
    Abstract: A method of diagnosing and selecting treatment for a urinary tract infection (UTI) in a subject having a neuropathic bladder (NB) is described. The method includes screening the subject for UTI risk; selecting a proper lower urinary symptom or UTI treatment if the determined risk exceeds a threshold, wherein the proper treatment is the administration of a therapeutically effective amount of a probiotic treatment to the subject and treating the subject.
    Type: Grant
    Filed: July 21, 2015
    Date of Patent: May 8, 2018
    Assignees: Medstar Health, Children's National Medical Center
    Inventors: Suzanne L. Groah, Hans G. Pohl, Ljubica Caldovic
  • Patent number: 9937213
    Abstract: The present finding relates to a composition comprising the probiotic Lactobacillus rhamnosus GG (ATCC 53103) for use in the prevention and/or treatment of herpes labialis and to a composition comprising the probiotic bacterial species and a soluble prebiotic fiber.
    Type: Grant
    Filed: June 26, 2014
    Date of Patent: April 10, 2018
    Assignee: GRANAROLO S.P.A.
    Inventors: Andrea Borsari, Vittorio Angelo Zambrini
  • Patent number: 9925204
    Abstract: A composition for treating inflammation and pain, including a hydrogen-generating compound in an amount that increases the amount of hydrogen in an individual and has an anti-inflammatory effect. A composition for treating inflammation and pain, including synergistically effective amounts of pregabalin and lactulose. A method of treating inflammation and pain, by administering a composition comprising a hydrogen-generating compound to an individual in an amount that increases the amount of hydrogen in the individual and has an anti-inflammatory effect.
    Type: Grant
    Filed: June 20, 2016
    Date of Patent: March 27, 2018
    Inventors: Toshihisa Kawai, Kenneth I. Kohn
  • Patent number: 9925225
    Abstract: An embodiment is a method of preventing, mitigating or treating Gastroesophageal Reflux Disease (GERD) that includes administering an effective amount of a medicament comprised of the Lactobacillus bulgaricus B-30892 strain and/or bioactive compounds from its supernatant to a human to prevent, mitigate or treat GERD.
    Type: Grant
    Filed: September 24, 2015
    Date of Patent: March 27, 2018
    Assignee: NuBiome, Inc.
    Inventor: Brian C. Lue
  • Patent number: 9919012
    Abstract: The subject invention provides materials and methods that effectively support innate immunity and/or disperse pathogenic biofilms using readily available, nontoxic, natural substances, while supporting restoration of normal microbiotic homeostasis. In one embodiment, the subject invention provides anti-biofilm compositions comprising one or more probiotic organisms, anti-microbial honey, and other ingredients such as prebiotic compounds, other hive products, green tea derivatives, other plant derivatives, and vitamin D3.
    Type: Grant
    Filed: January 23, 2017
    Date of Patent: March 20, 2018
    Assignee: QUORUM INNOVATIONS, LLC
    Inventors: Eva A. Berkes, Nicholas T. Monsul, Frederick T. Boehm
  • Patent number: 9907755
    Abstract: The present invention relates to the development of a targeted delivery system for the oral delivery of probiotics or therapeutic agent for various indications, including and not limited to active and prophylaxis treatment of Clostridium difficile infection, antibiotic associated diarrhea, irritable bowel syndrome, Crohn's disease, intestinal flora replacement, supplemental flora treatments for patients taking antibiotics, and for restoration of balance and signaling between the intestinal microbiome and the intestinal cells in patients under treatment of metabolic syndrome manifestations, specifically diabetes, insulin resistance, obesity, hyperlipidemia and hypertension.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: March 6, 2018
    Assignee: Therabiome, LLC
    Inventors: Mohan Kabadi, Jerome J. Schentag
  • Patent number: 9895427
    Abstract: Compositions and methods for treating or preventing E. coli infections are provided. The compositions can be formulated as pharmaceutical compositions or as disinfectants, sanitizers, detergents or antiseptics, and can be used to eradicate or reduce E. coli populations and thereby treat or prevent infection by E. coli. The compositions include one or more digestive enzymes, e.g., one or more protease, lipases, and amylases. Methods of use of the compositions are also provided.
    Type: Grant
    Filed: May 15, 2015
    Date of Patent: February 20, 2018
    Assignee: GALENAGEN, LLC
    Inventors: Joan M. Fallon, Matthew Heil, James J. Fallon
  • Patent number: 9855293
    Abstract: Disclosed is a non-reducing end unsaturated mannuronic acid oligosaccharide having a molecular weight of 100-3000 Da, which is obtained by lysing polymannuronate as a substrate with alginate lyase, and provided are: a non-reducing end unsaturated mannuronic acid oligosaccharide; and pharmaceutical compositions for alleviating, preventing, or treating obesity, diabetes, and climacteric syndrome, and probiotics for promoting intestinal beneficial bacteria, the compositions and probiotics containing, as an active ingredient, the non-reducing end unsaturated mannuronic acid oligosaccharide, so that the antiobesity and antidiabetic effects, estrogen activity, and intestinal microflora controlling effect of the non-reducing end unsaturated mannuronic acid oligosaccharides are remarkably excellent as compared with non-reducing end saturated mannuronic acid oligosaccharides.
    Type: Grant
    Filed: March 14, 2016
    Date of Patent: January 2, 2018
    Assignee: INDUSTRY FOUNDATION OF CHONNAM NATIONAL UNIVERSITY
    Inventor: Du Woon Kim
  • Patent number: 9839684
    Abstract: The present invention relates to pharmaceutical compositions comprising a mixture of a specific HIV antigen and a non-pathogenic living bacterium. Said specific HIV antigen comprises one or more epitopes from Gag and/or Pol proteins and is preferably under a particulate form. Said bacterium is preferably Lactobacillus plantarum. These compositions are useful for preventing and/or treating an HIV disease in humans.
    Type: Grant
    Filed: April 6, 2012
    Date of Patent: December 12, 2017
    Assignees: BIOVAXIM LIMITED, UNIVERSITE PARIS DESCARTES, INSTITUT DE RECHERSCHE POUR LE DEVELOPPEMENT (IRD)
    Inventors: Jean-Marie Andrieu, Louis Lu
  • Patent number: 9808475
    Abstract: Oligosaccharides from bovine milk, whey and dairy products, and methods of producing bovine milk oligosaccharides are provided.
    Type: Grant
    Filed: September 30, 2015
    Date of Patent: November 7, 2017
    Assignee: The Regents of the University of California
    Inventors: J. Bruce German, David Mills, Carlito B. Lebrilla, Daniela Barile, Riccardo LoCascio
  • Patent number: 9795579
    Abstract: A method of promoting a desired oral microbiota in a subject to treat an allergy related respiratory condition, the method including providing an edible composition including an amino acid containing ingredient comprising L-arginine wherein the composition is provided contained and at least partially dissolved within an oral cavity of the subject for a period of at least from about 10 seconds to about an hour on a daily basis of at least two consecutive days.
    Type: Grant
    Filed: April 24, 2017
    Date of Patent: October 24, 2017
    Assignee: KNOZE JR. CORPORATION
    Inventor: Shunsheng Han
  • Patent number: 9789140
    Abstract: The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of Bacteroides, Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, E. coli, Gemmiger, Desulfomonas, Peptostreptococcus, and fungi. The present invention also provides pharmaceutical compositions suitable for the treatment of the same chronic diseases comprising viable non-pathogenic or attenuated pathogenic Escherichia coli, at least one strain of viable non-pathogenic or attenuated pathogenic Bacteroides and at least one strain of viable non-pathogenic or attenuated pathogenic microorganism.
    Type: Grant
    Filed: September 9, 2016
    Date of Patent: October 17, 2017
    Assignee: Crestovo Holdings LLC
    Inventor: Thomas Julius Borody
  • Patent number: 9757442
    Abstract: The invention relates to the use of lactic acid-producing bacteria to boost the immune system.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: September 12, 2017
    Assignee: Ganeden Biotech, Inc.
    Inventors: Sean Farmer, Michael A. Bush, David Keller
  • Patent number: 9744208
    Abstract: The invention described herein provides for methods and systems for determining, selecting, and/or treating diseases and conditions caused by or associated with high quantities of methanogens in a subject, or diseases and conditions caused by or associated with low quantities of methanogens in a subject. In various embodiments, a therapy to inhibit the growth of methanogens or to promote the growth of methanogens are selected and/or administered to a subject in need thereof.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: August 29, 2017
    Assignee: CEDARS-SINAI MEDICAL CENTER
    Inventors: Mark Pimentel, Ruchi Mathur, Christopher Chang
  • Patent number: 9713630
    Abstract: The disclosure provides oral compositions and methods of using such compositions in treating subjects infected with one or more hepatic disorders. The compositions include lysates or cell wall extracts of one or more gram positive bacteria, exhibit particular activity against hepatitis C virus (HCV), and may be useful in treating those infected with HCV as well as other hepatic diseases or disorders. Also described are methods of treating a hepatic disease or disorder by administering a therapeutically effective amount of at least one therapeutically active agent capable of upregulating or downregulating the Complement system pathway, wherein the therapeutically active agent enhances the formation of one or more convertase enzymes.
    Type: Grant
    Filed: January 16, 2013
    Date of Patent: July 25, 2017
    Assignee: Labyrinth Holdings, LLC
    Inventor: Elizabeth McKenna
  • Patent number: 9707207
    Abstract: The invention provides for methods of treating autism associated with Desulfovibrio overgrowth in the gastrointestinal tract of a patient, said method comprising administering to the patient suffering from said autism a treatment course of aztreonam in an amount effective to treat autism in the patient, thereby treating autism.
    Type: Grant
    Filed: May 26, 2011
    Date of Patent: July 18, 2017
    Assignee: The United States of America as represented by the Department of Veterans Affairs
    Inventor: Sydney Martin Finegold
  • Patent number: 9687513
    Abstract: The present invention relates to the use of at least one strain of Lactobacillus plantarum chosen from the group comprising Lactobacillus plantarum 299, DSM 6595, Lactobacillus plantarum '299v, DSM 9843, Lactobacillus plantarum HEAL 9, DSM 15312, Lactobacillus plantarum HEAL 19, DSM 15313, Lactobacillus plantarum HEAL 99, DSM 15316, and a part thereof, for the preparation of a composition for increasing the absorption of at least one kind of metal/metal ion in a mammal, preferably a human.
    Type: Grant
    Filed: July 4, 2006
    Date of Patent: June 27, 2017
    Assignee: Probi AB
    Inventors: Jan Alenfall, Anna Berggren
  • Patent number: 9649346
    Abstract: The invention relates to an anhydrous mixture of biologically active probiotic bacteria for topical administration and methods of making thereof. The mixture of the invention is used for hydrating the skin, reducing and preventing fine lines and wrinkles, treating acne and decreasing skin inflammation.
    Type: Grant
    Filed: November 1, 2012
    Date of Patent: May 16, 2017
    Inventor: Andrew M. Klapper
  • Patent number: 9649380
    Abstract: The present invention relates to compositions comprising probiotic and prebiotic components, mineral salts, lactoferrin, and possibly saccharomycetes, which perform correct, effective colonisation of the probiotic components administered, with enteric consequences which involve maintaining and/or restoring intestinal health and preventing the consequences of common dysbioses of the digestive tract caused by stress, incorrect dietary habits and antibiotic treatments. Said compositions also have a concomitant anti-inflammatory and immunomodulating action.
    Type: Grant
    Filed: July 11, 2011
    Date of Patent: May 16, 2017
    Assignee: Pfizer Italia S.R.L.
    Inventors: Valeria Longoni, Marisa Penci
  • Patent number: 9642874
    Abstract: The present application relates to compositions comprising selenium compounds, such as 5?-Methylselenoadenosine, Se-Adenosyl-L-homocysteine, Gamma-glutamyl-methylseleno-cysteine, a compound of Formula (I), Formula (II), or Formula (III), and combinations thereof, and methods of using the same for modulating glucose metabolism in a subject.
    Type: Grant
    Filed: September 15, 2015
    Date of Patent: May 9, 2017
    Assignee: Alltech, Inc.
    Inventors: Ronan Power, Zi-Jian Lan
  • Patent number: 9616094
    Abstract: The present invention relates generally to the field of nutrition, more particularly to the use of probiotics in nutrition. In particular the present invention relates to the use of a probiotic or of a mixture of probiotics in the manufacture of a nutritional composition or a medicament to act the colon in a pre- or post surgical environment.
    Type: Grant
    Filed: August 23, 2013
    Date of Patent: April 11, 2017
    Assignee: Nestec S.A.
    Inventor: Eduardo Schiffrin